Agios Pharmaceuticals, Inc. (AGIO) saw its stock price plummet by 50.27% to $22.62 after releasing Phase 3 trial results for mitapivat in sickle cell disease. The study showed that 40.6% of patients on mitapivat achieved a hemoglobin response compared to 2.9% on placebo, with improvements in hemoglobin concentration and bilirubin levels. However, the drug did not meet statistical significance for sickle-cell pain crises or fatigue. The company plans to discuss a marketing application with the FDA in Q1 2026, focusing on its rare-disease pipeline and managing costs post-PYRUKYND approval for thalassemia. Trading volume spiked as investors digested the news, with the stock’s 52-week range at $12.34 – $48.75.

Read more at Nasdaq: Agios Shares Plunge 50% After Mixed Phase 3 RISE UP Results For Mitapivat